Holen Sie sich die Stockscreener-App
12.61
0.08%
0.010
Handel nachbörslich:
12.60
-0.010
-0.08%
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Avoiding Lag: Real-Time Signals in (NTLA) Movement - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation - MSN
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout
Intellia Drops Counterclaims In Gene-Editing Patent Case - Law360
Intellia Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit - Bloomberg Law News
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test By Investing.com - Investing.com Nigeria
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test - Investing.com
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance
Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise? - Sahm
Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win - CoinCentral
Intellia Therapeutics FDA rolling application for gene therapy puts hype to test - MSN
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
NTLA Q1 earnings beat estimates, revenues miss mark, pipeline in focus - MSN
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress - Sahm
Intellia Therapeutics (NTLA) slides as investors digest recent earnings and dilution overhang - Quiver Quantitative
Discipline and Rules-Based Execution in NTLA Response - Stock Traders Daily
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline - Sahm
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
NTLA Maintained by Bernstein -- Price Target Raised to $17.00 - GuruFocus
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25 - Moomoo
NTLA Maintains by HC Wainwright & Co. -- Price Target Lowered to $25 - GuruFocus
Wedbush Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution By Investing.com - Investing.com South Africa
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail
High Growth Tech Stocks In The US For May 2026 - simplywall.st
NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN
Intellia Therapeutics Price Target Cut to $49.00/Share From $58.00 by Canaccord Genuity - Moomoo
Transcript : Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03 - marketscreener.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares - Investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares By Investing.com - Investing.com India
Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19 - Moomoo
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus - TradingView
NTLA Reiterated by Wedbush -- Price Target Maintained at $12 - GuruFocus
Intellia short interest rises most among biotech stocks in latest periodBaird - Investing.com
Intellia Therapeutics Stock Short Interest Rises to 39.28% - Quiver Quantitative
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
How Investors May Respond To Intellia Therapeutics (NTLA) Raising Capital And Advancing Its CRISPR HAE Therapy - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics Inc earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
NTLA SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Need to drop to 14 bf it take off.. - Moomoo
Intellia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Intellia (NTLA) Reports Strong Q1 Revenue and Achievements in Ge - GuruFocus
Intellia Therapeutics, Inc. Q1 2026 Financial Results and SEC Filing Overview - Minichart
[Dad's Options Dojo: Today's Idea] May 12, 2026 ■ Ticker: Intellia Therapeutics (NTLA) / Biotechnology - Moomoo
Intellia Therapeutics, Inc. (NTLA) reports Q1 loss, misses revenue estimates - MSN
Intellia Therapeutics Reports Positive Phase 3 Lonvo-z Data for HAE, Rolling BLA Submission, and Strong Q1 2026 Financials - Minichart
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):